Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect.

DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.

DM21-L-G is a Drug-Linker Conjugates that can be used to synthesize ADC molecules.

DL5055 (compound 6k) is a potent and selective hCAR activator with an EC50 of 0.35 μM. DL5055 induces CYP2B6 expression and hCAR nuclear translocation in human primary hepatocytes.

DL-01 TFA is the TFA salt form of DL-01. GSK-364735 potassium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-

Dihydroxyacetone phosphate dilithium (DHAP) is used for studies of fructose metabolism, trioses and glycosylation. Dihydroxyacetone phosphate dilithium is used for studies involving the metabolism of trisaccharide pools and their roles in physiological and physical processes.

Diclofenac amide is a prodrug for Diclofenac sodium. Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan-induced rat paw edema model without causing gastric ulcer (300 μmol/kg).

Desthiazolylmethyl ritonavir is a base-catalyzed degradation product of the HIV protease inhibitor Ritonavir, black: linker, Blue: E3 ligase ligand).

DEL-I25 is a potent GPX4 activator. DEL-I25 protects cells from ferroptosis.

Defactinib analogue-1 (Compound 7) is a ligand for target protein Fak, that can be used for synthesis of PROTAC FAK degrader 1. 11(Z),14(Z)-Eicosadienoic acid ethanolamide inhibits the inactivating transport of an endogenous cannabinoid substance with an IC50 value of 10.6 μM. 11(Z),14(Z)-Eicosadienoic acid ethanolamide can be used for research of neuropsychiatric conditions.

DDO-6691 is a heat shock protein 90 (HSP90) inhibitor. DDO-6691 has antiproliferative effects on a variety of tumor cells, with HCT-116 colon cancer cells being the most sensitive (IC50: 1.08 μM). DDO-6691 exhibits potent tumor growth inhibition in the HCT-116 xenograft mouse model.

DDO-6079 is a potent CDC37 inhibitor. DDO-6079 inhibits HSP90-CDC37 and CDC37-CDK4/6 chaperone complex by binding to an allosteric site on CDC37. DDO-6079 decreases the thermostability of CDK6.

DDL-357 is a potent secreted clusterin enhancer. DDL-357 reduces phospho-tau in brain and improves memory in the murine 3xTg-AD model.

DDHF20 is an antimicrobial agent against Staphylococcus aureus, targeting and inhibiting its thioredoxin reductase (TrxR). It acts as a competitive inhibitor for the NADPH binding site. DDHF20 is expected to be used in research related to antimicrobial infections caused by Staphylococcus aureus.

DCG04 isomer-1 is an isomer of DCG04.

DC20 is an orally active non-nucleoside reverse transcriptase inhibitor with an EC50 of 0.004 μM aganist HIV-1IIIB.

DBL-6-13 is an inhibitor for WDR5 with a moderate binding affinity of 6.8 μM (microscale thermophoresis assay) and 9.1 μM (fluorescence polarization assay).

DBCO-PEG3-NHS is a biochemical assay reagent, that can be used to chemically modify proteins and antibodies with an alkynyl (DBCO) or N-hydroxysuccinimide (NHS) ester group. DBCO-PEG3-NHS can be used as a linker in PROTAC synthesis or for drug delivery and the development of biosensors and diagnostic reagents.

DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

Darlifarnib (Compound (S)-058) is the inhibitor for farnesyl transferase and geranylgeranyltransferase with IC50 ≤ 10 nM and ＞ 1000 nM. Darlifarnib exhibits good metabolic stability in human and mouse liver microsomes with the half-life time ＞ 100 min.

Danifexor is the agonist for farnesoid X receptor.

DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study.

Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model.

Cy3-PEG-FA (MW 2000) is a fluorescent folate-PEG derivative with excitation/emission wavelengths of ~550 nm/~570 nm. Cy3-PEG-FA (MW 2000) can be readily traced by its intense red fluorescent signal. Cy3-PEG-FA (MW 2000) can be used for cell imaging, folate receptor targeting and detection.

CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.

CTT2274 is a prodrug of MMAE analog. SPA107 inhibits the polymerization of tubulin, exhibits antimitotic activity (IC50 of 0.5 nM) and cytotoxicity in p53 mutated MCF-7 cell with IC50 of 0.5 nM.

CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research.

CPW-86-363 is a novel broad-spectrum cephalosporin with antibacterial activity.

CP-865569 is a CCR1 antagonist. CP-865569 can be used in the research of inflammatory diseases and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

CP-506 (compound 26) mesylate is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity.